Cytokines and immune response in the tumor microenvironment

S. Mocellin, E. Wang, F. M. Marincola

Research output: Contribution to journalReview article

181 Citations (Scopus)

Abstract

Over the last few decades a wealth of evidence has been gathered on the potential role that the immune system (IS) can play in the fight against cancer. Together with cell surface adhesion molecules, cytokines (CKs) mediate the activities of IS cells. Therefore, CK kinetics may represent a mirror of the immunologic phenomena occurring in the tumor microenvironment, where immune and malignant cells interact. Yet, CKs are currently used in a clinical setting to polarize the immune response against cancer. Despite the large amount of information available on IS physiology, little is known about the role of CKs in modulating the effectiveness of immunotherapy clinical trials aimed at the treatment of patients with cancer. This underscores our relative ignorance about the complex cascade of events that lead to tumor rejection. Here, we review the properties of some CKs believed to be particularly relevant to tumor immunology (i.e., interleukin [IL]-10, transforming growth factor-β, interferon-γ, IL-2, IL-4, and IL-12). We summarized the experience gained with these CKs in vitro, in animal models, and in human beings to illustrate the achievements, the controversies, and the challenges that characterize this fascinating field of oncology. In addition, we added a short section in which a broad view of CKs released in the tumor microenvironment is proposed to underline the variety of factors that contribute to the complexity of tumor-IS interactions.

Original languageEnglish
Pages (from-to)392-407
Number of pages16
JournalJournal of Immunotherapy
Volume24
Issue number5
DOIs
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Tumor Microenvironment
Cytokines
Immune System
Neoplasms
Cell Adhesion Molecules
Transforming Growth Factors
Interleukin-12
Allergy and Immunology
Interleukin-4
Interleukin-10
Immunotherapy
Interferons
Interleukin-2
Animal Models
Clinical Trials

Keywords

  • Cytokine
  • Immune response
  • Immunotherapy
  • Tumor

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Immunology

Cite this

Cytokines and immune response in the tumor microenvironment. / Mocellin, S.; Wang, E.; Marincola, F. M.

In: Journal of Immunotherapy, Vol. 24, No. 5, 2001, p. 392-407.

Research output: Contribution to journalReview article

Mocellin, S. ; Wang, E. ; Marincola, F. M. / Cytokines and immune response in the tumor microenvironment. In: Journal of Immunotherapy. 2001 ; Vol. 24, No. 5. pp. 392-407.
@article{fcec309760344062b7e9296d0c9e2141,
title = "Cytokines and immune response in the tumor microenvironment",
abstract = "Over the last few decades a wealth of evidence has been gathered on the potential role that the immune system (IS) can play in the fight against cancer. Together with cell surface adhesion molecules, cytokines (CKs) mediate the activities of IS cells. Therefore, CK kinetics may represent a mirror of the immunologic phenomena occurring in the tumor microenvironment, where immune and malignant cells interact. Yet, CKs are currently used in a clinical setting to polarize the immune response against cancer. Despite the large amount of information available on IS physiology, little is known about the role of CKs in modulating the effectiveness of immunotherapy clinical trials aimed at the treatment of patients with cancer. This underscores our relative ignorance about the complex cascade of events that lead to tumor rejection. Here, we review the properties of some CKs believed to be particularly relevant to tumor immunology (i.e., interleukin [IL]-10, transforming growth factor-β, interferon-γ, IL-2, IL-4, and IL-12). We summarized the experience gained with these CKs in vitro, in animal models, and in human beings to illustrate the achievements, the controversies, and the challenges that characterize this fascinating field of oncology. In addition, we added a short section in which a broad view of CKs released in the tumor microenvironment is proposed to underline the variety of factors that contribute to the complexity of tumor-IS interactions.",
keywords = "Cytokine, Immune response, Immunotherapy, Tumor",
author = "S. Mocellin and E. Wang and Marincola, {F. M.}",
year = "2001",
doi = "10.1097/00002371-200109000-00002",
language = "English",
volume = "24",
pages = "392--407",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Cytokines and immune response in the tumor microenvironment

AU - Mocellin, S.

AU - Wang, E.

AU - Marincola, F. M.

PY - 2001

Y1 - 2001

N2 - Over the last few decades a wealth of evidence has been gathered on the potential role that the immune system (IS) can play in the fight against cancer. Together with cell surface adhesion molecules, cytokines (CKs) mediate the activities of IS cells. Therefore, CK kinetics may represent a mirror of the immunologic phenomena occurring in the tumor microenvironment, where immune and malignant cells interact. Yet, CKs are currently used in a clinical setting to polarize the immune response against cancer. Despite the large amount of information available on IS physiology, little is known about the role of CKs in modulating the effectiveness of immunotherapy clinical trials aimed at the treatment of patients with cancer. This underscores our relative ignorance about the complex cascade of events that lead to tumor rejection. Here, we review the properties of some CKs believed to be particularly relevant to tumor immunology (i.e., interleukin [IL]-10, transforming growth factor-β, interferon-γ, IL-2, IL-4, and IL-12). We summarized the experience gained with these CKs in vitro, in animal models, and in human beings to illustrate the achievements, the controversies, and the challenges that characterize this fascinating field of oncology. In addition, we added a short section in which a broad view of CKs released in the tumor microenvironment is proposed to underline the variety of factors that contribute to the complexity of tumor-IS interactions.

AB - Over the last few decades a wealth of evidence has been gathered on the potential role that the immune system (IS) can play in the fight against cancer. Together with cell surface adhesion molecules, cytokines (CKs) mediate the activities of IS cells. Therefore, CK kinetics may represent a mirror of the immunologic phenomena occurring in the tumor microenvironment, where immune and malignant cells interact. Yet, CKs are currently used in a clinical setting to polarize the immune response against cancer. Despite the large amount of information available on IS physiology, little is known about the role of CKs in modulating the effectiveness of immunotherapy clinical trials aimed at the treatment of patients with cancer. This underscores our relative ignorance about the complex cascade of events that lead to tumor rejection. Here, we review the properties of some CKs believed to be particularly relevant to tumor immunology (i.e., interleukin [IL]-10, transforming growth factor-β, interferon-γ, IL-2, IL-4, and IL-12). We summarized the experience gained with these CKs in vitro, in animal models, and in human beings to illustrate the achievements, the controversies, and the challenges that characterize this fascinating field of oncology. In addition, we added a short section in which a broad view of CKs released in the tumor microenvironment is proposed to underline the variety of factors that contribute to the complexity of tumor-IS interactions.

KW - Cytokine

KW - Immune response

KW - Immunotherapy

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=0034763562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034763562&partnerID=8YFLogxK

U2 - 10.1097/00002371-200109000-00002

DO - 10.1097/00002371-200109000-00002

M3 - Review article

VL - 24

SP - 392

EP - 407

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 5

ER -